OX-40 Receptor Emerging as a Novel Target in Cancer Immunotherapy
Oct 23, 2017
OX-40 receptor agonist currently exhibits a viable pipeline with nine drug candidates, P&S Market Research
October 23, 2017 /MarketersMedia/ —
The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.
Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample
According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.
Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.
Pre-Purchase Enquiry : https://www.psmarketresearch.com/send-enquiry?enquiry-url=ox40-receptor-agonist-therapeutics-pipeline
In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.
OX-40 Receptor Agonist Therapeutics Pipeline Analysis
By Phase
By Molecule Type
By Route of Administration
By Company
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Contact Info:
Name: Kundan Kumar
Organization: P&S Market Research
Source URL: https://marketersmedia.com/ox-40-receptor-emerging-as-a-novel-target-in-cancer-immunotherapy/253416
For more information, please visit https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline
Source: MarketersMedia
Release ID: 253416
More News
Fuel costs squeezing margins for some businesses
Diesel recently topped £2 per litre and there is concern that a duty freeze will not go far enough.
'TV and cheap booze' blamed for landlord quitting
Lincolnshire has lost 27% of its pubs and bars since 2009 and some are calling on the government to act against cheap supermarket booze.
Ship attack reports near Hormuz reach record high as oil exports slow
BBC Verify analysis of data from a UK maritime agency shows 12 vessels were struck in a week.
Netflix Replaces Bela Bajaria as Chief Content Officer
Peter Rice, a former executive at Disney and Fox, will take over from Bela Bajaria, who had held the job since 2023.
Living with a stink? Technology might help
Smells from rubbish dumps and industrial facilities are being more carefully monitored.
I find it quite demoralising in store - why I do all my shopping online
After Primark announced plans for home delivery, we hear from women who never go into clothes stores.
Gulf Oil Is Still Flowing Despite a Surge in Attacks on Ships
Shipping operators are braving the Strait of Hormuz, but the risks are high and transportation costs have skyrocketed.
Tech Stocks Drop Further Amid Doubts Over AI Spending
Tech stocks plunged before reversing course, as concerns over soaring A.I. spending and stubborn inflation fueled a sell-off.
'I'd spend $1,000 on a wedding present'
New Yorkers share how much they spend on a wedding gift - and how they decide.
Homeownership Drifts Further Out of Reach as Mortgage Rates Rise
Mortgage rates have pushed above 7 percent and home prices remain elevated, hurting the prospects of would-be buyers.
'I paid thousands to a company for jobs that never came'
Apurv Patel is one of several people who say they were promised job opportunities that did not appear.
Data Centers Become Targets in Wars in Ukraine, Russia and the Middle East
Military forces have sought to damage the computing hubs that power online services and artificial intelligence systems.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.